Literature DB >> 28681401

Prevalence and outcome of late-onset seizures due to autoimmune etiology: A prospective observational population-based cohort study.

Felix von Podewils1, Marie Suesse1, Julia Geithner2, Bernadette Gaida1, Zhong I Wang3, Julia Lange1, Alexander Dressel1,4, Matthias Grothe1, Christof Kessler1, Soenke Langner5, Uwe Runge1, Christian G Bien6.   

Abstract

OBJECTIVE: The increasing incidence of new-onset seizures with age is well known. Often, the etiology cannot be clarified. In the present study, patients with unprovoked late-onset seizures and without known neoplasm, who might have had paraneoplastic encephalitis, were investigated for a potentially underlying autoimmunity.
METHODS: Sixty-six consecutive patients (36 women; aged ≥55 years) after having at least one seizure or seizures for ≤6 months were prospectively identified over a period of 4.75 years. All patients were tested for serum and cerebrospinal fluid (CSF) antibodies (Abs) to both neural cell-surface and intracellular antigens. Forty-five (68%) underwent brain magnetic resonance imaging (MRI). Follow-up in Ab-positive cases was ≥6 months.
RESULTS: Two patients had high titers of anti-CASPR2 (contactin-associated protein-like 2) Abs in serum and CSF and fulfilled the diagnostic criteria of definite limbic encephalitis. Another two patients had bilateral encephalitic temporal MRI abnormalities. They also satisfied the criteria of definite limbic encephalitis, even though they had no Abs in serum or CSF. All four were in the age range of 55-70 years. They received immunotherapy and/or antiepileptic drug treatment and became seizure-free. SIGNIFICANCE: Our findings suggest that autoimmunity should be considered an important etiology in patients with late-onset seizures. Testing for neural antibodies and brain MRI may be worthwhile in this patient group. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  Autoimmune etiology; Late-onset seizures; Neural antibodies

Mesh:

Substances:

Year:  2017        PMID: 28681401     DOI: 10.1111/epi.13834

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

1.  Brain morphological and microstructural features in cryptogenic late-onset temporal lobe epilepsy: a structural and diffusion MRI study.

Authors:  Daichi Sone; Noriko Sato; Yukio Kimura; Yutaka Watanabe; Mitsutoshi Okazaki; Hiroshi Matsuda
Journal:  Neuroradiology       Date:  2018-04-13       Impact factor: 2.804

2.  Incidence of Adult-Onset Epilepsy and the Contributory Role of Neurocysticercosis in a Five-Year, Population-Based, Prospective Study in Rural Ecuador.

Authors:  Oscar H Del Brutto; Bettsy Y Recalde; Robertino M Mera
Journal:  Am J Trop Med Hyg       Date:  2021-10-11       Impact factor: 3.707

3.  Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis.

Authors:  Tetyana Blinder; Jan Lewerenz
Journal:  Front Neurol       Date:  2019-07-25       Impact factor: 4.003

4.  Improvement in anti-N-methyl-d-aspartate receptor antibody-mediated temporal lobe epilepsy with amygdala enlargement without immunotherapy.

Authors:  Go Taniguchi; Hitomi Fuse; Yumiko Okamura; Harushi Mori; Shinsuke Kondo; Kiyoto Kasai; Yukitoshi Takahashi; Keiko Tanaka
Journal:  Epilepsy Behav Case Rep       Date:  2018-08-03

5.  HMGB1/CXCL12-Mediated Immunity and Th17 Cells Might Underlie Highly Suspected Autoimmune Epilepsy in Elderly Individuals.

Authors:  Yuxiang Han; Liling Yang; Xiaoyun Liu; Yabo Feng; Zaiying Pang; Youting Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-19       Impact factor: 2.570

6.  Adult-onset temporal lobe epilepsy suspicious for autoimmune pathogenesis: Autoantibody prevalence and clinical correlates.

Authors:  Julia C Kuehn; Carolin Meschede; Christoph Helmstaedter; Rainer Surges; Randi von Wrede; Elke Hattingen; Hartmut Vatter; Christian E Elger; Susanne Schoch; Albert J Becker; Julika Pitsch
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.